|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Project Title** | | | | | **Funding Requested** |
|  | | | | |  |
| **KEY PERSONNEL**  *Please attach a current NIH Biosketch for each key person.* | | | | | |
| **Name** (First Last, Degrees) | **Professional Title** | **Department/Division** | **Role on Project** | **Institution**  (e.g., UCI, CHOC, LBVA) | |
|  |  |  | **Contact PI** |  | |
|  |  |  |  |  | |
|  |  |  |  |  | |
|  |  |  |  |  | |
| **PROJECT DETAILS** | | | | | |
| **Project Descriptors** | | | | *Enter an “X” for all that apply* | |
| One or more of the PIs are early-stage investigators ([as defined by NIH](https://grants.nih.gov/policy/early-stage/index.htm)). | | | |  | |
| The project addresses [cancer health disparities](https://www.cancer.gov/about-cancer/understanding/disparities) in the catchment area. | | | |  | |
| The project addresses unique aspects of a specific cancer burden in the [catchment area.](https://www.cancer.uci.edu/about/catchment-area) | | | |  | |
| The project includes collaborations with a [Disease-Oriented Team or multidisciplinary tumor board](http://cancer.uci.edu/disease-oriented-teams.asp) to advance a novel diagnostic or screening technology, therapeutic molecule or device, or bio-behavioral intervention to a clinical trial. | | | |  | |
| Research conducted will enable extramural funding for an Investigator-Initiated Trial (IIT) in the detection or prevention of cancer. | | | |  | |
| The project utilizes one or more of the following [CFCCC Shared Resource](http://cancer.uci.edu/shared-resources.asp)s below. Check all that apply.   |  |  | | --- | --- | | Transgenic Mouse Facility (TMF)  Optical Biology Core (OBC)  Genomics High-Throughput Facility (GHTF)  In Vivo Functional Onco-Imaging (IVFOI) | Experimental Tissue Resource (ETR)  Biostatistic Shared Resource (BSR)  Biobehavioral Shared Resource (BBSR) | | | | |  | |

|  |  |
| --- | --- |
| **TRACK** | |
| **Which track is the project most aligned with?** | *Enter an “X” for all that apply* |
| **Track 1** projects are basic, translational, or population-based cancer science projects limited to one year. These applications are expected to generate pilot data necessary for obtaining peer-reviewed extramural grants (such as an NIH R01) or enable additional data collection to respond to prior critiques for resubmission applications (NIH A1 applications). |  |
| **Track 2** projects support Early Phase Clinical Research, with the goal of launching an interventional investigator-initiated interventional clinical trial at UCI Health within a 2-year time frame. While Track 2 projects are not necessarily expected to lead to extramural peer-reviewed funding, pharmaceutical industry co-sponsorship is encouraged. These projects must be managed by the Stern Center for Cancer Clinical Trials & Research and must meet the following criteria:   * + Be initiated from a Disease-Oriented Team or a multidisciplinary tumor board   + Include a DOT-approved clinical protocol   + Be capable of obtaining full regulatory approval (e.g., IRB) within 6 months of the award. |  |

**Scientific Abstract** (30 lines,Margins .5", Font: Arial 11 point)

|  |
| --- |
| The project summary is a succinct and accurate description of the proposed work and should be able to stand on its own (separate from the application). This section should be informative to other persons working in the same or related fields and understandable to a scientifically literate reader. Avoid both descriptions of past accomplishments and the use of the first person. Please be concise. |
| **Lay Audience Summary** (3-4 sentences,Margins .5", Font: Arial 11 point) |
| Using non-technical language, provide a clear overview of the research project in a way that can be easily understood by the general public. The lay summary should allow the public to understand the research and its value, impact, and applications to public health. If the application is funded, the summary and scientific abstract will become public information and will be shared with donors, the general public and the media. |

**Research Strategy** (3 pages max excluding references, Margins .5", Font: Arial 11 point.)

Provide Full Description of the Project

* Background and Significance
* Research Plan and Specific Aims
* A succinct rationale for requested funds through this funding mechanism (no more than half a page).
  + For Track 1 projects, please describe how this pilot project will lead to an extramural grant application. You should note the agency and request for proposal you will submit to, and discuss your timetable for submitting your application, the key preliminary data needed to be responsive to the call, and the critical experiments that are needed. For resubmissions, please discuss the outcome of the initial review (i.e., was your application triaged or scored), what were the key critiques, and what key experiments will you run to resolve them.
  + For Track 2 projects, discuss your specific plans for launching an investigator-initiated treatment trial at UC Irvine, including plans for securing pharmaceutical industry co-sponsorship or other extramural support.

**Bibliography/References Cited** (no page limit)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Budget**   * Awards are limited to $40,000 of total direct costs. As these are gift funds, no indirect costs will be awarded. * Applications are limited to one year of support for Track 1 projects and 2 years of support for Track 2 projects. Track 2 projects do not need to include separate period budgets—one aggregate budget is sufficient. * Unallowable costs:PI salaries (salaries for project staff are allowable), large equipment (e.g., >$5K), travel, and indirect costs. | | | | | |
| **PERSONNEL** |  |  |  | | |
|  |  |  | DOLLAR AMOUNT REQUESTED | | |
|  | ROLE ON | % EFFORT OR CALENDAR MONTHS | SALARY | FRINGE | TOTALS |
| NAME | PROJECT |  | REQUESTED | BENEFITS |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| **PERSONNEL SUBTOTAL** | | | | |  |
| **SUPPLIES** |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  | **SUPPLY SUBTOTAL** | | | |  |
| **OTHER EXPENSES** |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  | **OTHER EXENSES SUBTOTAL** | | |  |
| **TOTAL REQUESTED** | | | | | **$0** |

**Budget Justification** (1 page maximum)

**For Resubmission Applications Only**

|  |
| --- |
| For previously unsuccessful applications, an introduction to the resubmission is now allowed. The summary should:   * summarize substantial additions, deletions, and changes to the application * respond to the issues and criticism raised by mentors or previous reviews.   **Resubmission Summary** (1/2 page maximum,Margins .5", Font: Arial 11 point) |
|  |